U.S. anorexiants market is projected to register a CAGR of 3.5% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:
U.S. Anorexiants Market, By Drug Class (Catecholamines Anorexiants, Serotonin Anorexiants), Drug Type (Generics, Branded), Applications (Weight Loss, Obesity, Attention Deficit Hyperactivity Disorder (ADHD), Dravet Syndrome), Prescription Mode (Prescription, OTC), Route of Administration (Oral, Parenteral), End User (Hospitals, Specialty Clinics, Home Healthcare), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of the U.S. anorexiants market are:

• Rising prevalence of obesity in the U.S. anorexiants market
• Increasing level of stress in the U.S. anorexiants market

Market Players:

The key market players for the U.S. anorexiants market are listed below:

• VIVUS Inc.
• KVK Tech, Inc.
• Currax Pharmaceuticals LLC.
• Recordati Rare Diseases (a subsidiary of RECORDATI S.p.A.)
• Aurobindo Pharma USA (a subsidiary of Aurobindo Pharma)
• Sun Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Teva Pharmaceutical USA Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)
• sanofi-aventis U.S. LLC (A Subsidiary of Sanofi)
• Hikma Pharmaceuticals PLC
• Lannett
• Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila)
• Dr. Reddy’s Laboratories Ltd.
• Sandoz AG (a business division of Novartis AG)
• Mylan N.V.
• Bausch Health Companies Inc.
• Cipla Inc.
• Par Pharmaceutical (a subsidiary of Endo International plc)
• Amphastar Pharmaceuticals, Inc.